Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 327

1.

SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer.

van den Boorn HG, Abu-Hanna A, Ter Veer E, van Kleef JJ, Lordick F, Stahl M, Ajani JA, Guimbaud R, Park SH, Dutton SJ, Bang YJ, Boku N, Mohammad NH, Sprangers MAG, Verhoeven RHA, Zwinderman AH, van Oijen MGH, van Laarhoven HWM.

Cancers (Basel). 2019 Feb 5;11(2). pii: E187. doi: 10.3390/cancers11020187.

2.

Outcomes and prognostic factors after pulmonary metastasectomy in patients with colorectal cancer with previously resected hepatic metastases.

Shimizu K, Ohtaki Y, Okumura T, Boku N, Horio H, Takenoyama M, Yamashita M, Hyodo I, Mori K, Kondo H.

J Thorac Cardiovasc Surg. 2019 Jan 11. pii: S0022-5223(19)30002-9. doi: 10.1016/j.jtcvs.2018.12.075. [Epub ahead of print]

PMID:
30745042
3.

Prognostic Value of Primary Tumor Sidedness for Unresectable Stage IV Colorectal Cancer: A Retrospective Study.

Shida D, Tanabe T, Boku N, Takashima A, Yoshida T, Tsukamoto S, Kanemitsu Y.

Ann Surg Oncol. 2019 Feb 4. doi: 10.1245/s10434-019-07209-x. [Epub ahead of print]

PMID:
30719633
4.

Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial.

Yoshikawa T, Terashima M, Mizusawa J, Nunobe S, Nishida Y, Yamada T, Kaji M, Fukushima N, Hato S, Choda Y, Yabusaki H, Yoshida K, Ito S, Takeno A, Yasuda T, Kawachi Y, Katayama H, Fukuda H, Boku N, Sano T, Sasako M.

Lancet Gastroenterol Hepatol. 2019 Mar;4(3):208-216. doi: 10.1016/S2468-1253(18)30383-2. Epub 2019 Jan 22.

PMID:
30679107
5.

Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer.

Yamaguchi T, Iwasa S, Shoji H, Honma Y, Takashima A, Kato K, Hamaguchi T, Higuchi K, Boku N.

Gastric Cancer. 2019 Jan 2. doi: 10.1007/s10120-018-00917-5. [Epub ahead of print]

PMID:
30603911
6.

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase 2 trial (ATTRACTION-4).

Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW, Cho H, Kang WK, Komatsu Y, Tsuda M, Yamaguchi K, Hara H, Fumita S, Azuma M, Chen LT, Kang YK.

Ann Oncol. 2018 Dec 19. doi: 10.1093/annonc/mdy540. [Epub ahead of print]

PMID:
30566590
7.

A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2).

Kato K, Satoh T, Muro K, Yoshikawa T, Tamura T, Hamamoto Y, Chin K, Minashi K, Tsuda M, Yamaguchi K, Machida N, Esaki T, Goto M, Komatsu Y, Nakajima TE, Sugimoto N, Yoshida K, Oki E, Nishina T, Tsuji A, Fujii H, Kunieda K, Saitoh S, Omuro Y, Azuma M, Iwamoto Y, Taku K, Fushida S, Chen LT, Kang YK, Boku N.

Gastric Cancer. 2018 Dec 1. doi: 10.1007/s10120-018-0899-6. [Epub ahead of print]

PMID:
30506519
8.

Primary Tumor Resection for Stage IV Colorectal Cancer in the Era of Targeted Chemotherapy.

Shida D, Boku N, Tanabe T, Yoshida T, Tsukamoto S, Takashima A, Kanemitsu Y.

J Gastrointest Surg. 2018 Nov 27. doi: 10.1007/s11605-018-4044-y. [Epub ahead of print]

PMID:
30484063
9.

TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).

Ioka T, Ueno M, Ueno H, Park JO, Chang HM, Sasahira N, Kanai M, Chung IJ, Ikeda M, Nakamori S, Mizuno N, Omuro Y, Yamaguchi T, Hara H, Sugimori K, Furuse J, Maguchi H, Furukawa M, Fukuzawa K, Kim JS, Yukisawa S, Takeuchi M, Okusaka T, Boku N, Hyodo I.

Eur J Cancer. 2019 Jan;106:78-88. doi: 10.1016/j.ejca.2018.10.004. Epub 2018 Nov 22.

10.

Efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from colorectal cancer: a propensity score-matched analysis.

Imanishi M, Yamamoto Y, Hamano Y, Yamada T, Moriwaki T, Gosho M, Okumura T, Boku N, Kondo H, Hyodo I.

Eur J Cancer. 2019 Jan;106:69-77. doi: 10.1016/j.ejca.2018.10.003. Epub 2018 Nov 22.

PMID:
30471650
11.

aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.

Fujita Y, Taguri M, Yamazaki K, Tsurutani J, Sakai K, Tsushima T, Nagase M, Tamagawa H, Ueda S, Tamura T, Tsuji Y, Murata K, Taira K, Denda T, Moriwaki T, Funai S, Nakajima TE, Muro K, Tsuji A, Yoshida M, Suyama K, Kurimoto T, Sugimoto N, Baba E, Seki N, Sato M, Shimura T, Boku N, Hyodo I, Yamanaka T, Nishio K.

Oncologist. 2018 Nov 13. pii: theoncologist.2018-0119. doi: 10.1634/theoncologist.2018-0119. [Epub ahead of print]

PMID:
30425180
12.

Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption.

Kikuchi K, Nozawa K, Yamazaki N, Nakai Y, Higashiyama A, Asano M, Fujiwara Y, Kanda S, Ohe Y, Takashima A, Boku N, Inoue A, Takahashi M, Mori T, Taguchi O, Inoue Y, Mizutani H.

J Dermatol. 2019 Jan;46(1):18-25. doi: 10.1111/1346-8138.14691. Epub 2018 Nov 7.

PMID:
30402978
13.

Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design.

Moehler M, Ryu MH, Dvorkin M, Lee KW, Coşkun HŞ, Wong R, Chung HC, Poltoratsky A, Tsuji A, Yen CJ, Muntean AS, Le Sourd S, Vaccaro GM, Overton L, Boku N, Wainberg ZA, Patel M, Sharma M, Xiong H, Conti I, Taieb J, Bang YJ.

Future Oncol. 2019 Feb;15(6):567-577. doi: 10.2217/fon-2018-0668. Epub 2018 Oct 31.

14.

A phase III trial to confirm modified S-1 adjuvant chemotherapy for pathological stage II/III vulnerable elderly gastric cancer patients who underwent gastric resection (JCOG1507, BIRDIE).

Mizutani T, Yamaguchi K, Mizusawa J, Ito S, Nishida Y, Yabusaki H, Boku N, Sano T, Yoshida K, Sasako M, Yoshikawa T, Terashima M; Stomach Cancer Study Group/Japan Clinical Oncology Group.

Jpn J Clin Oncol. 2018 Dec 1;48(12):1101-1104. doi: 10.1093/jjco/hyy152.

PMID:
30346560
15.

Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study.

Ida H, Honma Y, Hirano H, Shoji H, Iwasa S, Okita N, Takashima A, Kato K, Fukuda T, Boku N.

Invest New Drugs. 2018 Sep 28. doi: 10.1007/s10637-018-0669-7. [Epub ahead of print]

PMID:
30267338
16.

Selection of Second-line Anti-angiogenic Agents After Failure of Bevacizumab-containing First-line Chemotherapy in Metastatic Colorectal Cancer.

Boku N, Yamamoto S.

Clin Colorectal Cancer. 2018 Dec;17(4):251-254. doi: 10.1016/j.clcc.2018.07.012. Epub 2018 Aug 1.

PMID:
30149985
17.

Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.

Bang YJ, Ruiz EY, Van Cutsem E, Lee KW, Wyrwicz L, Schenker M, Alsina M, Ryu MH, Chung HC, Evesque L, Al-Batran SE, Park SH, Lichinitser M, Boku N, Moehler MH, Hong J, Xiong H, Hallwachs R, Conti I, Taieb J.

Ann Oncol. 2018 Oct 1;29(10):2052-2060. doi: 10.1093/annonc/mdy264.

18.

Retrospective Analyses of Systemic Chemotherapy and Cytoreductive Surgery for Patients with Ovarian Metastases from Colorectal Cancer: A Single-Center Experience.

Sekine K, Hamaguchi T, Shoji H, Takashima A, Honma Y, Iwasa S, Kato K, Takahashi K, Kato T, Kanemitsu Y, Boku N.

Oncology. 2018;95(4):220-228. doi: 10.1159/000489665. Epub 2018 Jul 20.

PMID:
30032147
19.

Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy.

Beumer JH, Chu E, Allegra C, Tanigawara Y, Milano G, Diasio R, Kim TW, Mathijssen RH, Zhang L, Arnold D, Muneoka K, Boku N, Joerger M.

Clin Pharmacol Ther. 2019 Mar;105(3):598-613. doi: 10.1002/cpt.1124. Epub 2018 Sep 11. Review.

PMID:
29923599
20.

Imaging peritoneal metastasis of gastric cancer with 18F-fluorothymidine positron emission tomography/computed tomography: a proof-of-concept study.

Honma Y, Terauchi T, Tateishi U, Kano D, Nagashima K, Shoji H, Iwasa S, Takashima A, Kato K, Hamaguchi T, Boku N, Shimada Y, Yamada Y.

Br J Radiol. 2018 Sep;91(1089):20180259. doi: 10.1259/bjr.20180259. Epub 2018 Jun 27.

PMID:
29916721
21.

Randomized phase 3 and extension studies: Efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer.

Katakami N, Harada T, Murata T, Shinozaki K, Tsutsumi M, Yokota T, Arai M, Tada Y, Narabayashi M, Boku N.

Ann Oncol. 2018 Apr 18. doi: 10.1093/annonc/mdy118. [Epub ahead of print]

22.

The current status of multimodality treatment for unresectable locally advanced esophageal squamous cell carcinoma.

Hirano H, Boku N.

Asia Pac J Clin Oncol. 2018 Jun 5. doi: 10.1111/ajco.12995. [Epub ahead of print] Review.

PMID:
29873183
23.

Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial.

Takashima A, Shitara K, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Kimura Y, Amagai K, Fujii H, Muro K, Esaki T, Choda Y, Takano T, Chin K, Sato A, Goto M, Fukushima N, Hara T, Machida N, Ohta M, Boku N, Shimura M, Morita S, Koizumi W.

Gastric Cancer. 2019 Jan;22(1):155-163. doi: 10.1007/s10120-018-0838-6. Epub 2018 May 31.

24.

Questionnaire survey on adjuvant chemotherapy for elderly patients after gastrectomy indicates their vulnelabilities.

Tanahashi T, Yoshida K, Yamaguchi K, Okumura N, Takeno A, Fujitani K, Fukushima N, Takiguchi N, Nishida Y, Boku N, Yoshikawa T, Terashima M.

Gastric Cancer. 2019 Jan;22(1):130-137. doi: 10.1007/s10120-018-0834-x. Epub 2018 May 24.

PMID:
29799059
25.

Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.

Taieb J, Moehler M, Boku N, Ajani JA, Yañez Ruiz E, Ryu MH, Guenther S, Chand V, Bang YJ.

Cancer Treat Rev. 2018 May;66:104-113. doi: 10.1016/j.ctrv.2018.04.004. Epub 2018 Apr 22. Review.

26.

Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan.

Todaka A, Mizuno N, Ozaka M, Ueno H, Kobayashi S, Uesugi K, Kobayashi N, Hayashi H, Sudo K, Okano N, Horita Y, Kamei K, Yukisawa S, Nakamori S, Yachi Y, Henmi T, Kobayashi M, Boku N, Mori K, Fukutomi A.

Pancreas. 2018 May/Jun;47(5):631-636. doi: 10.1097/MPA.0000000000001049.

PMID:
29683973
27.

Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis.

Iizumi S, Takashima A, Sakamaki K, Morita S, Boku N.

Cancer Chemother Pharmacol. 2018 Jun;81(6):981-989. doi: 10.1007/s00280-018-3569-9. Epub 2018 Mar 29.

PMID:
29600386
28.

Shorter survival in adolescent and young adult patients, compared to adult patients, with stage IV colorectal cancer in Japan.

Shida D, Ahiko Y, Tanabe T, Yoshida T, Tsukamoto S, Ochiai H, Takashima A, Boku N, Kanemitsu Y.

BMC Cancer. 2018 Mar 27;18(1):334. doi: 10.1186/s12885-018-4241-9.

29.

Type of second primary malignancy after achieving complete response by definitive chemoradiation therapy in patients with esophageal squamous cell carcinoma.

Yamaguchi T, Kato K, Nagashima K, Iwasa S, Honma Y, Takashima A, Hamaguchi T, Ito Y, Itami J, Boku N, Higuchi K.

Int J Clin Oncol. 2018 Aug;23(4):652-658. doi: 10.1007/s10147-018-1258-7. Epub 2018 Mar 8.

PMID:
29520523
30.

Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01).

Hagiwara Y, Ohashi Y, Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T; JASPAC 01 Study Group.

Eur J Cancer. 2018 Apr;93:79-88. doi: 10.1016/j.ejca.2018.01.081. Epub 2018 Mar 20.

PMID:
29477795
31.

Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy.

Ito Y, Tsuda T, Minatogawa H, Kano S, Sakamaki K, Ando M, Tsugawa K, Kojima Y, Furuya N, Matsuzaki K, Fukuda M, Sugae S, Ohta I, Arioka H, Tokuda Y, Narui K, Tsuboya A, Suda T, Morita S, Boku N, Yamanaka T, Nakajima TE.

J Clin Oncol. 2018 Apr 1;36(10):1000-1006. doi: 10.1200/JCO.2017.74.4375. Epub 2018 Feb 14.

PMID:
29443652
32.

A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma.

Hiramoto S, Kato K, Shoji H, Okita N, Takashima A, Honma Y, Iwasa S, Hamaguchi T, Yamada Y, Shimada Y, Boku N.

Int J Clin Oncol. 2018 Jun;23(3):466-472. doi: 10.1007/s10147-018-1239-x. Epub 2018 Jan 20.

PMID:
29353337
33.

First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study.

Makiyama A, Kunieda K, Noguchi M, Kajiwara T, Tamura T, Takeda K, Sugiyama J, Minashi K, Moriwaki T, Sugimoto N, Nagase M, Negoro Y, Tsuda T, Shimodaira H, Okano N, Tsuji A, Sakai D, Yanagihara K, Ueda S, Tamura S, Otsu S, Honda T, Matsushita Y, Okuno T, Kashiwada T, Nozaki A, Ebi M, Okuda H, Shimokawa M, Hironaka S, Hyodo I, Baba E, Boku N, Muro K, Esaki T.

Gastric Cancer. 2018 Sep;21(5):792-801. doi: 10.1007/s10120-018-0797-y. Epub 2018 Jan 20.

PMID:
29353332
34.

Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer.

Kusumoto T, Sunami E, Ota M, Yoshida K, Sakamoto Y, Tomita N, Maeda A, Mochizuki I, Okabe M, Kunieda K, Yamauchi J, Itabashi M, Kotake K, Takahashi K, Baba H, Boku N, Aiba K, Ishiguro M, Morita S, Sugihara K.

Clin Colorectal Cancer. 2018 Jun;17(2):e153-e161. doi: 10.1016/j.clcc.2017.10.015. Epub 2017 Nov 1.

35.

The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy.

Shoji H, Tada K, Kitano S, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Takashima A, Kato K, Boku N, Honda K, Yamada T, Heike Y, Hamaguchi T.

Oncotarget. 2017 May 30;8(56):95083-95094. doi: 10.18632/oncotarget.18297. eCollection 2017 Nov 10.

36.
37.

Reply.

Hishida T, Tsuboi M, Okumura T, Boku N, Hyodo I, Mori K, Kondo H.

Ann Thorac Surg. 2017 Dec;104(6):2123. doi: 10.1016/j.athoracsur.2017.03.048. No abstract available.

PMID:
29153795
38.

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.

Bang YJ, Xu RH, Chin K, Lee KW, Park SH, Rha SY, Shen L, Qin S, Xu N, Im SA, Locker G, Rowe P, Shi X, Hodgson D, Liu YZ, Boku N.

Lancet Oncol. 2017 Dec;18(12):1637-1651. doi: 10.1016/S1470-2045(17)30682-4. Epub 2017 Nov 2.

PMID:
29103871
39.

Patterns of Relapse after Definitive Chemoradiotherapy in Stage II/III (Non-T4) Esophageal Squamous Cell Carcinoma.

Sudo K, Kato K, Kuwabara H, Sasaki Y, Takahashi N, Shoji H, Iwasa S, Honma Y, Okita NT, Takashima A, Hamaguchi T, Yamada Y, Ito Y, Itami J, Fukuda T, Tobinai K, Boku N.

Oncology. 2018;94(1):47-54. doi: 10.1159/000480515. Epub 2017 Oct 28.

PMID:
29080886
40.

Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm.

Sawaki A, Yamada Y, Yamaguchi K, Nishina T, Doi T, Satoh T, Chin K, Boku N, Omuro Y, Komatsu Y, Hamamoto Y, Koizumi W, Saji S, Shah MA, Van Cutsem E, Kang YK, Iwasaki J, Kuriki H, Ohtsuka W, Ohtsu A.

Gastric Cancer. 2018 May;21(3):429-438. doi: 10.1007/s10120-017-0773-y. Epub 2017 Oct 20.

41.

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT.

Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6.

PMID:
28993052
42.

Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.

Katakami N, Harada T, Murata T, Shinozaki K, Tsutsumi M, Yokota T, Arai M, Tada Y, Narabayashi M, Boku N.

J Clin Oncol. 2017 Dec 1;35(34):3859-3866. doi: 10.1200/JCO.2017.73.0853. Epub 2017 Oct 2.

PMID:
28968171
43.

Reply.

Hishida T, Tsuboi M, Okumura T, Boku N, Hyodo I, Mori K, Kondo H.

Ann Thorac Surg. 2017 Oct;104(4):1435-1436. doi: 10.1016/j.athoracsur.2017.03.047. No abstract available.

PMID:
28935314
44.

Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study.

Hagiwara Y, Ohashi Y, Okusaka T, Ueno H, Ioka T, Boku N, Egawa S, Hatori T, Furuse J, Mizumoto K, Ohkawa S, Yamaguchi T, Yamao K, Funakoshi A, Cheng AL, Kihara K, Sato A, Tanaka M.

ESMO Open. 2017 Mar 15;2(1):e000151. doi: 10.1136/esmoopen-2016-000151. eCollection 2017.

45.

Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study.

Iizumi S, Takashima A, Narita Y, Tajika M, Muro K, Kawai S, Yasui H, Matsushima T, Takahari D, Nagashima K, Boku N.

Cancer Chemother Pharmacol. 2017 Sep;80(3):575-582. doi: 10.1007/s00280-017-3397-3. Epub 2017 Jul 20.

PMID:
28730292
46.

Clinical Outcomes of Resectable Esophageal Cancer with Supraclavicular Lymph Node Metastases Treated with Curative Intent.

Honma Y, Hokamura N, Nagashima K, Sudo K, Shoji H, Iwasa S, Takashima A, Kato K, Hamaguchi T, Boku N, Umezawa R, Ito Y, Itami J, Koyanagi K, Igaki H, Tachimori Y.

Anticancer Res. 2017 Jul;37(7):3741-3749.

PMID:
28668869
47.

Esophageal Metastasis from Rectal Cancer Successfully Treated with Fluorouracil-Based Chemotherapy with Bevacizumab: A Case Report and Review of the Literature.

Watanabe S, Takashima A, Taniguchi H, Tanaka Y, Nakamura S, Okita N, Honma Y, Iwasa S, Kato K, Hamaguchi T, Boku N.

Case Rep Oncol. 2017 May 5;10(2):407-415. doi: 10.1159/000474939. eCollection 2017 May-Aug.

48.

Surgical Outcome and Prognostic Stratification for Pulmonary Metastasis From Colorectal Cancer.

Okumura T, Boku N, Hishida T, Ohde Y, Sakao Y, Yoshiya K, Higashiyama M, Hyodo I, Mori K, Kondo H.

Ann Thorac Surg. 2017 Sep;104(3):979-987. doi: 10.1016/j.athoracsur.2017.03.021. Epub 2017 Jun 1.

PMID:
28577846
49.

Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G).

Miura Y, Sukawa Y, Hironaka S, Mori M, Nishikawa K, Tokunaga S, Okuda H, Sakamoto T, Taku K, Nishikawa K, Moriwaki T, Negoro Y, Kimura Y, Uchino K, Shinozaki K, Shinozaki H, Musha N, Yoshiyama H, Tsuda T, Miyata Y, Sugimoto N, Shirakawa T, Ito M, Yonesaka K, Yoshimura K, Boku N, Nosho K, Takano T, Hyodo I.

Gastric Cancer. 2018 Jan;21(1):84-95. doi: 10.1007/s10120-017-0725-6. Epub 2017 May 11.

PMID:
28497176
50.

Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer.

Katakami N, Oda K, Tauchi K, Nakata K, Shinozaki K, Yokota T, Suzuki Y, Narabayashi M, Boku N.

J Clin Oncol. 2017 Jun 10;35(17):1921-1928. doi: 10.1200/JCO.2016.70.8453. Epub 2017 Apr 26.

PMID:
28445097

Supplemental Content

Support Center